Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Malignant Lymphoma

Free Subscription Articles published in Leukemia Retrieve available abstracts of 97 articles: HTML format

Single Articles

February 2026
1. MADIOT C, Bellanger C, Dousset C, Decombis S, et al
   CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.
   Leukemia. 2026 Feb 19. doi: 10.1038/s41375-026-02894.
   PubMed     Abstract available
   
   
   
2. FILIP D, Litzmanova K, Michaelou A, Kledus F, et al
   Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.
   Leukemia. 2026 Feb 19. doi: 10.1038/s41375-026-02868.
   PubMed     Abstract available
   
   
   
3. LANDSBURG DJ, Musoke N, Gentile C, Brooks TR, et al
   Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.
   Leukemia. 2026 Feb 17. doi: 10.1038/s41375-026-02870.
   PubMed    
   
   
   
4. GAO J, Zhao X, Yin Q, Hu A, et al
   Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.
   Leukemia. 2026 Feb 12. doi: 10.1038/s41375-026-02884.
   PubMed     Abstract available
   
   
   
5. YANG ZZ, Kim HJ, Tang X, Novak JP, et al
   Malignant B cells expressing SIRPalpha are highly proliferative and are associated with inferior clinical outcomes in B-cell non-Hodgkin lymphoma.
   Leukemia. 2026 Feb 4. doi: 10.1038/s41375-026-02872.
   PubMed    
   
   
   
6. NIKKARINEN A, Almlof J, Osterroos A, Ladenvall C, et al
   Accumulation of high-risk genetic features after chemoimmunotherapy: A longitudinal study in mantle cell lymphoma.
   Leukemia. 2026 Feb 4. doi: 10.1038/s41375-026-02861.
   PubMed    
   
   
   
7. STEIN CM, Hablesreiter R, Christen F, Lowe P, et al
   Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.
   Leukemia. 2026;40:314-324.
   PubMed     Abstract available
   
   
   January 2026
8. GRAF CM, Reese M, Vicente-Luque A, Monig N, et al
   Establishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft model.
   Leukemia. 2026 Jan 26. doi: 10.1038/s41375-025-02849.
   PubMed    
   
   
   November 2025
9. VALLOIS D, Missiaglia E, Veloza L, Fischer A, et al
   Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.
   Leukemia. 2025 Nov 20. doi: 10.1038/s41375-025-02808.
   PubMed    
   
   
   
10. WEI W, Song Z, Wang Y, Li S, et al
    The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma.
    Leukemia. 2025 Nov 12. doi: 10.1038/s41375-025-02809.
    PubMed     Abstract available
    
    
    
11. SUTO K, Takei N, Yokoyama K, Chiba M, et al
    Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.
    Leukemia. 2025 Nov 10. doi: 10.1038/s41375-025-02811.
    PubMed    
    
    
    
12. KURZ KS, Zamo A, Drewes C, Madej E, et al
    Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving concept.
    Leukemia. 2025 Nov 7. doi: 10.1038/s41375-025-02794.
    PubMed     Abstract available
    
    
    
13. MOIA R, Ragaini S, Cascione L, Rinaldi A, et al
    The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial.
    Leukemia. 2025 Nov 7. doi: 10.1038/s41375-025-02795.
    PubMed    
    
    
    
14. KHOUJA M, Genuardi E, Ferrero S, Laqua A, et al
    Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.
    Leukemia. 2025 Nov 3. doi: 10.1038/s41375-025-02787.
    PubMed     Abstract available
    
    
    
15. THAPA R, Nichols KE, Sharma R
    Insights into germline predisposition to pediatric lymphoid malignancies.
    Leukemia. 2025;39:2590-2602.
    PubMed     Abstract available
    
    
    October 2025
16. KHOUJA M, Kehden B, Blair D, Kuffer C, et al
    ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.
    Leukemia. 2025 Oct 27. doi: 10.1038/s41375-025-02759.
    PubMed     Abstract available
    
    
    
17. VALLOIS D, Missiaglia E, Veloza L, Fischer A, et al
    Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.
    Leukemia. 2025 Oct 7. doi: 10.1038/s41375-025-02777.
    PubMed     Abstract available
    
    
    
18. ZHANG J, Wang D, Luan M, Liu X, et al
    Liquid-liquid phase separation of ZHX2 protects DLBCL cells against ferroptosis through induction of SLC3A2.
    Leukemia. 2025;39:2442-2451.
    PubMed     Abstract available
    
    
    September 2025
19. NADEU F, Shuai S, Clot G, Hilton LK, et al
    Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms.
    Leukemia. 2025;39:2076-2086.
    PubMed     Abstract available
    
    
    August 2025
20. SUZUKI K, Kusayanagi S, Kuze Y, Hata M, et al
    Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF-beta axis in adult T-cell leukemia/lymphoma.
    Leukemia. 2025 Aug 4. doi: 10.1038/s41375-025-02725.
    PubMed     Abstract available
    
    
    
21. BERG V, Lollies A, Schneider M, Johansson P, et al
    Common origin and somatic mutation patterns of composite lymphomas and leukemias.
    Leukemia. 2025;39:1960-1971.
    PubMed     Abstract available
    
    
    July 2025
22. HEAVICAN-FORAL TB, Korell F, Scarfo I, Wiggers CRM, et al
    Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma.
    Leukemia. 2025 Jul 30. doi: 10.1038/s41375-025-02697.
    PubMed     Abstract available
    
    
    
23. RAUSCH T, Schafer H, Bein J, Molder F, et al
    Genetic lesions in nodular lymphocyte-predominant Hodgkin lymphoma and T cell/histiocyte-rich large B-cell lymphoma identified by whole genome sequencing.
    Leukemia. 2025 Jul 16. doi: 10.1038/s41375-025-02679.
    PubMed     Abstract available
    
    
    
24. ZHAO SH, Zhu ZM, Yang T, Gao D, et al
    Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma.
    Leukemia. 2025 Jul 12. doi: 10.1038/s41375-025-02658.
    PubMed    
    
    
    
25. DUTTA D, Gouveia MH, Gorman BR, Adu-Gyamfi A, et al
    A genome-wide association study identifies an African-specific locus on chromosome 21q22.12 associated with Burkitt lymphoma risk and survival.
    Leukemia. 2025 Jul 11. doi: 10.1038/s41375-025-02690.
    PubMed     Abstract available
    
    
    
26. DONDOLIN R, Garrou F, Almasri M, Terzi Di Bergamo L, et al
    Integration of [(18)F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma.
    Leukemia. 2025 Jul 8. doi: 10.1038/s41375-025-02688.
    PubMed     Abstract available
    
    
    
27. MIELAND AO, Petrosino G, Dejung M, Chen JX, et al
    The protein deacetylase HDAC10 controls DNA replication in malignant lymphoid cells.
    Leukemia. 2025;39:1756-1768.
    PubMed     Abstract available
    
    
    June 2025
28. PEPE S, Vitale C, Giannarelli D, Visentin A, et al
    Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes.
    Leukemia. 2025 Jun 25. doi: 10.1038/s41375-025-02666.
    PubMed     Abstract available
    
    
    May 2025
29. FENG S, Kong R, Wang C, Hao Q, et al
    A highly selective and orally bioavailable casein kinase 1 alpha degrader through p53 signaling pathway targets B-cell lymphoma cells.
    Leukemia. 2025 May 27. doi: 10.1038/s41375-025-02647.
    PubMed     Abstract available
    
    
    
30. TARI CROCHET G, Ari-Yuka S, Fischer A, Chour M, et al
    Induction of p53-mediated apoptosis by azacitidine in patient-derived xenograft follicular helper T-cell lymphoma model.
    Leukemia. 2025 May 20. doi: 10.1038/s41375-025-02628.
    PubMed     Abstract available
    
    
    
31. EICHENAUER DA, Basaran A, Buhnen I, Fuchs M, et al
    Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
    Leukemia. 2025 May 13. doi: 10.1038/s41375-025-02641.
    PubMed     Abstract available
    
    
    
32. ITO Y, Shimono J, Kawamoto K, Hatanaka KC, et al
    TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma.
    Leukemia. 2025 May 2. doi: 10.1038/s41375-025-02631.
    PubMed     Abstract available
    
    
    April 2025
33. XAGORARIS I, Yang Y, Bougka E, Trogrlic D, et al
    Sulforaphane promotes natural killer cell-mediated anti-tumor immune responses partially via cGAS-STING pathway in classical Hodgkin lymphoma.
    Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02627.
    PubMed    
    
    
    
34. GAZEAU N, Beauvais D, Tilmont R, Srour M, et al
    Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?
    Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02605.
    PubMed     Abstract available
    
    
    
35. ZHOU T, Short NJ, Jain N, Patel KP, et al
    Age-related prognoses of genetic subtypes in B-cell acute lymphoblastic leukemia/lymphoma (B-ALL): insights from a decade of national data.
    Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02588.
    PubMed    
    
    
    
36. SUN C, Li W, Yu J, Zhang T, et al
    Molecular landscape of distinct follicular lymphoma histologic grades: insights from genomic and transcriptome analyses.
    Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02603.
    PubMed     Abstract available
    
    
    
37. KUEHN JC, Neidert NN, Zhang J, Mutter J, et al
    The effect of ibrutinib on the myeloid cell compartment in CNS lymphoma.
    Leukemia. 2025 Apr 10. doi: 10.1038/s41375-025-02600.
    PubMed    
    
    
    
38. ZRIMSEK M, Draganic K, Malzer A, Doblmayr V, et al
    HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy.
    Leukemia. 2025 Apr 2. doi: 10.1038/s41375-025-02584.
    PubMed     Abstract available
    
    
    
39. IACOBONI G, Rejeski K, Navarro V, van Meerten T, et al
    Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy.
    Leukemia. 2025 Apr 1. doi: 10.1038/s41375-025-02582.
    PubMed     Abstract available
    
    
    March 2025
40. SUEHARA Y, Sakamoto K, Fujisawa M, Fukumoto K, et al
    Discrete genetic subtypes and tumor microenvironment signatures correlate with peripheral T-cell lymphoma outcomes.
    Leukemia. 2025 Mar 31. doi: 10.1038/s41375-025-02563.
    PubMed     Abstract available
    
    
    
41. BROCKELMANN PJ, Muller H, Fuchs M, Gillessen S, et al
    Correction: Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.
    Leukemia. 2025 Mar 30. doi: 10.1038/s41375-025-02597.
    PubMed    
    
    
    
42. JERKEMAN M, Mellgren K, Sonnevi K, Lisak M, et al
    Implementation of standard of care CAR-T-cell treatment for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia in Sweden.
    Leukemia. 2025 Mar 26. doi: 10.1038/s41375-025-02573.
    PubMed    
    
    
    
43. BROCKELMANN PJ, Muller H, Fuchs M, Gillessen S, et al
    Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.
    Leukemia. 2025 Mar 24. doi: 10.1038/s41375-025-02567.
    PubMed    
    
    
    
44. LI S, Ren J, Wu J, Xia Z, et al
    Establishment and molecular characterisation of patient-derived organoids for primary central nervous system lymphoma.
    Leukemia. 2025 Mar 18. doi: 10.1038/s41375-025-02562.
    PubMed     Abstract available
    
    
    
45. ISABELLE C, Boles A, McConnell K, Keller R, et al
    CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention.
    Leukemia. 2025 Mar 8. doi: 10.1038/s41375-025-02551.
    PubMed     Abstract available
    
    
    February 2025
46. FUJIMOTO A, Miyazaki K, Yakushijin K, Fujino T, et al
    Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study.
    Leukemia. 2025 Feb 17. doi: 10.1038/s41375-025-02527.
    PubMed     Abstract available
    
    
    
47. SHAO Q, Bedi K, Malek IA, Shedden K, et al
    STAT6 mutations compensate for CREBBP mutations and hyperactivate IL4/STAT6/RRAGD/mTOR signaling in follicular lymphoma.
    Leukemia. 2025 Feb 5. doi: 10.1038/s41375-025-02525.
    PubMed     Abstract available
    
    
    January 2025
48. SIMON F, Al-Sawaf O, Seymour JF, Eichhorst B, et al
    Surrogate endpoints in mature B-cell neoplasms - meaningful or misleading?
    Leukemia. 2025;39:25-28.
    PubMed     Abstract available
    
    
    December 2024
49. CUI Q, Tan W, Song B, Peng RJ, et al
    Genetic susceptibility of diffuse large B-cell lymphoma: a meta genome-wide association study in Asian population.
    Leukemia. 2024 Dec 20. doi: 10.1038/s41375-024-02503.
    PubMed     Abstract available
    
    
    
50. SEIFERT N, Reinke S, Grund J, Muller-Meinhard B, et al
    T-cell diversity and exclusion of blood-derived T-cells in the tumor microenvironment of classical Hodgkin Lymphoma.
    Leukemia. 2024 Dec 17. doi: 10.1038/s41375-024-02490.
    PubMed     Abstract available
    
    
    
51. HAMPEL PJ, Rabe KG, Wang Y, Hwang SR, et al
    Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era.
    Leukemia. 2024 Dec 10. doi: 10.1038/s41375-024-02492.
    PubMed    
    
    
    November 2024
52. SHAW TI, Pounds S, Cao X, Ma J, et al
    Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma.
    Leukemia. 2024 Nov 26. doi: 10.1038/s41375-024-02468.
    PubMed     Abstract available
    
    
    
53. SENER OC, Melchers S, Tengler L, Beltzig PL, et al
    Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma.
    Leukemia. 2024 Nov 23. doi: 10.1038/s41375-024-02479.
    PubMed     Abstract available
    
    
    October 2024
54. PEREIRA JL, Arede L, Ferreira F, Matos A, et al
    Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma.
    Leukemia. 2024 Oct 25. doi: 10.1038/s41375-024-02446.
    PubMed     Abstract available
    
    
    
55. SUTO K, Takei N, Yokoyama K, Chiba M, et al
    Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.
    Leukemia. 2024 Oct 21. doi: 10.1038/s41375-024-02441.
    PubMed    
    
    
    
56. CORINALDESI C, Holmes AB, Martire G, Tosato A, et al
    Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance.
    Leukemia. 2024 Oct 18. doi: 10.1038/s41375-024-02431.
    PubMed     Abstract available
    
    
    
57. FRONTZEK F, Renaud L, Duhrsen U, Poeschel V, et al
    Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration.
    Leukemia. 2024;38:2225-2234.
    PubMed     Abstract available
    
    
    September 2024
58. LENZ G, Tilly H, Ziepert M, Altmann B, et al
    Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials.
    Leukemia. 2024 Sep 25. doi: 10.1038/s41375-024-02420.
    PubMed    
    
    
    
59. RAVANDI F, Senapati J, Jain N, Short NJ, et al
    Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Leukemia. 2024 Sep 25. doi: 10.1038/s41375-024-02414.
    PubMed     Abstract available
    
    
    
60. THIEBLEMONT C, Karimi YH, Ghesquieres H, Cheah CY, et al
    Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.
    Leukemia. 2024 Sep 25. doi: 10.1038/s41375-024-02410.
    PubMed     Abstract available
    
    
    
61. WILLIS BS, Mongeon K, Dry H, Neveras IL, et al
    Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma.
    Leukemia. 2024 Sep 16. doi: 10.1038/s41375-024-02401.
    PubMed     Abstract available
    
    
    
62. KHOUJA M, Jiang L, Pal K, Stewart PJ, et al
    Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials.
    Leukemia. 2024 Sep 16. doi: 10.1038/s41375-024-02375.
    PubMed     Abstract available
    
    
    August 2024
63. HE MY, Tong KI, Liu T, Whittaker Hawkins R, et al
    GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma.
    Leukemia. 2024 Aug 8. doi: 10.1038/s41375-024-02325.
    PubMed     Abstract available
    
    
    July 2024
64. HAN X, Sui J, Nie K, Zhao Y, et al
    Tumor evolution analysis uncovered immune-escape related mutations in relapse of diffuse large B-cell lymphoma.
    Leukemia. 2024 Jul 30. doi: 10.1038/s41375-024-02349.
    PubMed    
    
    
    
65. JINDAL U, Mamgain M, Nath UK, Sharma I, et al
    Correction: Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma.
    Leukemia. 2024 Jul 29. doi: 10.1038/s41375-024-02361.
    PubMed    
    
    
    
66. SPANJAART AM, Ljungman P, Tridello G, Schwartz J, et al
    Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP
    Leukemia. 2024 Jul 23. doi: 10.1038/s41375-024-02336.
    PubMed     Abstract available
    
    
    
67. MONDELLO P
    Silencing GNAS enhances HDAC3i efficacy in CREBBP wild type B cell lymphoma.
    Leukemia. 2024 Jul 19. doi: 10.1038/s41375-024-02355.
    PubMed     Abstract available
    
    
    
68. JINDAL U, Mamgain M, Nath UK, Sharma I, et al
    Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma.
    Leukemia. 2024 Jul 13. doi: 10.1038/s41375-024-02344.
    PubMed     Abstract available
    
    
    June 2024
69. LI Q, Liu Y, Wu J, Zhu Z, et al
    P4HA2 hydroxylates SUFU to regulate the paracrine Hedgehog signaling and promote B-cell lymphoma progression.
    Leukemia. 2024 Jun 22. doi: 10.1038/s41375-024-02313.
    PubMed     Abstract available
    
    
    
70. GIBOUIN VC, Durand M, Boudesco C, Hermetet F, et al
    First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma.
    Leukemia. 2024 Jun 21. doi: 10.1038/s41375-024-02302.
    PubMed     Abstract available
    
    
    
71. AWADA H, Gurnari C, Visconte V, Durmaz A, et al
    Clonal hematopoiesis-derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders.
    Leukemia. 2024;38:1266-1274.
    PubMed     Abstract available
    
    
    May 2024
72. LI Y, Chen K, Chen B, Zeng R, et al
    Increased coexpression of PD-L1 and IDO1 is associated with poor overall survival in patients with NK/T-cell lymphoma.
    Leukemia. 2024 May 23. doi: 10.1038/s41375-024-02266.
    PubMed     Abstract available
    
    
    
73. LIANG JH, Wu YF, Shen HR, Li Y, et al
    Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma.
    Leukemia. 2024 May 15. doi: 10.1038/s41375-024-02279.
    PubMed     Abstract available
    
    
    
74. WANG TP, Ahn KW, Shadman M, Kaur M, et al
    Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis.
    Leukemia. 2024 May 15. doi: 10.1038/s41375-024-02242.
    PubMed     Abstract available
    
    
    
75. CHIAPPELLA A, Casadei B, Chiusolo P, Di Rocco A, et al
    Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study.
    Leukemia. 2024;38:1107-1114.
    PubMed     Abstract available
    
    
    April 2024
76. FISCHER L, Jiang L, Durig J, Schmidt C, et al
    The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
    Leukemia. 2024 Apr 27. doi: 10.1038/s41375-024-02254.
    PubMed     Abstract available
    
    
    
77. REISS DJ, Nakayama Y, Weng AP, Stokes ME, et al
    High-plex imaging and cellular neighborhood spatial analysis reveals multiple immune escape and suppression patterns in diffuse large B-cell lymphoma.
    Leukemia. 2024 Apr 4. doi: 10.1038/s41375-024-02239.
    PubMed    
    
    
    March 2024
78. OERTEL M, Ziepert M, Frontzek F, Nacke N, et al
    Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trial.
    Leukemia. 2024 Mar 27. doi: 10.1038/s41375-024-02231.
    PubMed     Abstract available
    
    
    
79. GAO LR, Li X, Wang X, Liang Y, et al
    Treatment and survival for patients with localized primary ocular adnexal extranodal marginal zone lymphoma.
    Leukemia. 2024 Mar 19. doi: 10.1038/s41375-024-02227.
    PubMed    
    
    
    
80. LANTERMANS HC, Ma F, Kuil A, van Kesteren S, et al
    The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.
    Leukemia. 2024 Mar 7. doi: 10.1038/s41375-024-02207.
    PubMed     Abstract available
    
    
    February 2024
81. CHEN Z, Huang H, Huang H, Yu L, et al
    Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma.
    Leukemia. 2024 Feb 20. doi: 10.1038/s41375-024-02171.
    PubMed     Abstract available
    
    
    
82. HOLMQVIST AS, Meng Q, Dai C, Hageman L, et al
    Late morbidity and mortality after autologous blood or marrow transplantation for lymphoma in children, adolescents and young adults-a BMTSS report.
    Leukemia. 2024 Feb 19. doi: 10.1038/s41375-024-02144.
    PubMed     Abstract available
    
    
    
83. DELROCCO NJ, Loh ML, Borowitz MJ, Gupta S, et al
    Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report.
    Leukemia. 2024 Feb 15. doi: 10.1038/s41375-024-02166.
    PubMed     Abstract available
    
    
    
84. MANDHAIR HK, Radpour R, Westerhuis M, Banz Y, et al
    Analysis of autophagy in DLBCL reveals subtype-specific differences and the preferential targeting of ULK1 inhibition in GCB-DLBCL provides a rationale as a new therapeutic approach.
    Leukemia. 2024;38:424-429.
    PubMed    
    
    
    January 2024
85. KNAUFT J, Schenk T, Ernst T, Schnetzke U, et al
    Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis.
    Leukemia. 2024 Jan 18. doi: 10.1038/s41375-024-02135.
    PubMed     Abstract available
    
    
    
86. ZALA M, Lipinski B, Costechareyre C, Jarrosson L, et al
    Functional precision oncology for follicular lymphoma with patient-derived xenograft in avian embryos.
    Leukemia. 2024 Jan 15. doi: 10.1038/s41375-024-02150.
    PubMed    
    
    
    
87. LENZ G, Hawkes E, Verhoef G, Haioun C, et al
    Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
    Leukemia. 2024 Jan 10. doi: 10.1038/s41375-023-02133.
    PubMed    
    
    
    
88. LIU B, Zhao X, Zhang S, Li Q, et al
    Targeting ZDHHC21/FASN axis for the treatment of diffuse large B-cell lymphoma.
    Leukemia. 2024 Jan 9. doi: 10.1038/s41375-023-02130.
    PubMed     Abstract available
    
    
    
89. ZHANG C, Stelloo E, Barrans S, Cucco F, et al
    Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.
    Leukemia. 2024 Jan 6. doi: 10.1038/s41375-023-02134.
    PubMed     Abstract available
    
    
    December 2023
90. REN W, Wan H, Own SA, Berglund M, et al
    Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis.
    Leukemia. 2023 Dec 29. doi: 10.1038/s41375-023-02120.
    PubMed     Abstract available
    
    
    
91. ZHANG Q, Basappa J, Wang HY, Nunez-Cruz S, et al
    Chimeric kinase ALK induces expression of NAMPT and selectively depends on this metabolic enzyme to sustain its own oncogenic function.
    Leukemia. 2023;37:2436-2447.
    PubMed     Abstract available
    
    
    November 2023
92. PLAYA-ALBINYANA H, Arenas F, Royo R, Giro A, et al
    Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation.
    Leukemia. 2023 Nov 28. doi: 10.1038/s41375-023-02095.
    PubMed     Abstract available
    
    
    
93. SUMA S, Suehara Y, Fujisawa M, Abe Y, et al
    Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution.
    Leukemia. 2023 Nov 27. doi: 10.1038/s41375-023-02093.
    PubMed     Abstract available
    
    
    October 2023
94. FUCHS M, Jacob AS, Kaul H, Kobe C, et al
    Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
    Leukemia. 2023 Oct 16. doi: 10.1038/s41375-023-02064.
    PubMed     Abstract available
    
    
    
95. CASERTA C, Nucera S, Barcella M, Fazio G, et al
    miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease.
    Leukemia. 2023;37:1994-2005.
    PubMed     Abstract available
    
    
    
96. TIAN Z, Shi C, Yang G, Allen JK, et al
    Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.
    Leukemia. 2023;37:2006-2016.
    PubMed     Abstract available
    
    
    September 2023
97. BERNDT SI, Vijai J, Benavente Y, Camp NJ, et al
    Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.
    Leukemia. 2023 Sep 4. doi: 10.1038/s41375-023-01978.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum